Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Acquires $308,430.00 in Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) CEO Anthony S. Marucci acquired 11,500 shares of the company's stock in a transaction dated Monday, November 11th. The shares were acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the purchase, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Celldex Therapeutics Stock Up 3.1 %

Celldex Therapeutics stock traded up $0.80 during trading hours on Tuesday, hitting $27.01. 1,114,295 shares of the company traded hands, compared to its average volume of 874,178. The firm's 50-day simple moving average is $33.29 and its two-hundred day simple moving average is $35.72. The firm has a market cap of $1.79 billion, a P/E ratio of -10.65 and a beta of 1.60. Celldex Therapeutics, Inc. has a 1-year low of $24.43 and a 1-year high of $53.18.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently modified their holdings of CLDX. KBC Group NV lifted its position in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Celldex Therapeutics in the second quarter valued at about $76,000. Headlands Technologies LLC acquired a new position in Celldex Therapeutics during the first quarter worth about $147,000. CANADA LIFE ASSURANCE Co boosted its holdings in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock valued at $192,000 after acquiring an additional 955 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in Celldex Therapeutics by 34.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company's stock valued at $260,000 after purchasing an additional 1,582 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CLDX shares. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a report on Monday, September 30th. They set a "neutral" rating and a $45.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, November 7th. Finally, Wolfe Research downgraded Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a report on Friday, September 27th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $62.25.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.